Twist Bioscience Stock Price, News & Analysis

Twist Bioscience Corporation (NASDAQ: TWST) will release its financial results for the fiscal 2022 fourth quarter and full year on November 18, 2022, before market opening. A conference call and audio webcast will be held at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Twist specializes in synthetic DNA synthesis using its innovative silicon platform, producing products for various sectors like healthcare and agriculture. The financial results will be available on the company's website prior to the call.

Twist Bioscience Corporation (NASDAQ: TWST) and Illumina, Inc. (NASDAQ: ILMN) announced a partnership to enhance research capabilities with the co-branded Twist® for Illumina® Exome 2.0 Plus panel. Twist will manufacture the panel, which features high uniformity, low off-target rates, and is designed for Illumina sequencers. This collaboration aims to provide a market-leading exome panel, facilitating improved customer access to advanced genomic solutions. Both companies are recognized as leaders in genomics and next-generation sequencing.

Twist Bioscience Corporation (NASDAQ: TWST) has announced the promotion of Patrick Finn, Ph.D., to the role of president and chief operating officer. Dr. Finn, who previously served as chief commercial officer, has significantly contributed to the company's growth, increasing sales from $2 million in fiscal 2016 to $184 million for the 12 months ending June 30, 2022. His promotion is part of Twist's strategy to expand its global presence and enhance operational capabilities, aiming for increased market share in synthetic biology, NGS, and biopharma.

Twist Bioscience Corporation (NASDAQ: TWST) has launched the Twist Human Sample ID Kit, designed to track samples in next-generation sequencing (NGS) workflows. This innovation aims to minimize sample mix-ups, reducing the necessity for test re-runs and enhancing data accuracy. It is compatible with Twist NGS workflows, allowing quick identification of samples from whole blood. The kit will be showcased at the American Society of Human Genetics Annual Meeting on October 26, 2022, highlighting its capability of improving precision in genetic research.

Twist Bioscience Corporation (NASDAQ: TWST) has received the Great Place to Work Certification for the second consecutive year in the U.S. and additionally in China, Germany, Singapore, and the United Kingdom. A survey revealed that 85% of employees consider Twist a great workplace, significantly higher than the 57% average. CEO Emily M. Leproust emphasized the importance of company culture and announced the release of their first ESG report to showcase commitment to diversity and inclusion.

Twist Bioscience Corporation (NASDAQ: TWST) announced that Steffen Hellmold, SVP of Business Development for Data Storage, will present at the JSNN NanoImpacts 2022 conference from October 13-15, 2022 in Greensboro, NC. He will participate in a panel on October 13 and deliver a keynote on DNA data storage on October 14 at 9:00 AM ET. The conference aims to address advancements in synthetic biology and nanomaterials, following the 2018 SemiSynBio Roadmap.

Twist Bioscience (NASDAQ: TWST) has partnered with the Australian Research Council Centre of Excellence in Synthetic Biology (CoESB) to provide researchers with access to a wide range of Twist's DNA synthesis products. This collaboration aims to enhance research capabilities and foster the development of sustainable biobased products. Twist's proprietary technology will support the design of novel organisms for transforming agricultural waste into valuable products, contributing to a sustainable economy in Australia.

Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust will present at the Baird 2022 Global Healthcare Conference on September 13th at 2:35 p.m. ET in New York. The presentation will be webcast live, and a replay will be available for 30 days. Twist is a leader in synthetic biology, utilizing a proprietary silicon-based technology to manufacture synthetic DNA for various industries, including healthcare and agriculture. The company's focus includes synthetic genes and NGS preparation tools, with future ambitions in DNA data storage and biologics discovery.

Twist Bioscience Corporation (NASDAQ: TWST) reported record revenue of $56.1 million for 3QFY22, reflecting a 60% increase from $35.0 million in the same quarter of fiscal 2021. Total orders soared 53% to $59.7 million. The company raised its revenue guidance to $203 million for fiscal 2022. Despite growth, a net loss of $60.5 million was recorded, translating to $1.08 per share. R&D expenses rose to $36.8 million, while cash reserves stood strong at $527.6 million.